Shots:
- The CHMP has recommended Brinsupri (Brensocatib) for treating NCFB pts (≥12yrs.) with two or more exacerbations in the prior 12 mos.
- Opinion was based on P-III (ASPEN) trial (n=1721) & P-II (WILLOW) trial (n=256) assessing Brinsupri (10 or 25mg, PO) vs PBO in NCFB pts for 52 & 24wks., respectively, with WILLOW enrolling pts who had ≥2 documented pulmonary exacerbations in 12mos. prior to screening, both published in the NEJM
- Brinsupri is a QD, oral DPP1 inhibitor approved in the US for treating NCFB pts (≥12yrs.). It targets neutrophil serine proteases to reduce airway inflammation and is also being studied for other neutrophil-driven diseases
Ref: Insmed| Image: Insmed| Press Release
Related News:- Insmed Reports the US FDA’s Approval of Brinsupri (Brensocatib) for Non-Cystic Fibrosis Bronchiectasis (NCFB)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
